Sihuan Pharmaceutical Holdings Stock Net Income
| SHPHF Stock | USD 0.17 0.00 0.00% |
As of the 14th of February 2026, Sihuan Pharmaceutical has the Risk Adjusted Performance of 0.0918, coefficient of variation of 979.49, and Variance of 213.22. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sihuan Pharmaceutical, as well as the relationship between them. Please validate Sihuan Pharmaceutical standard deviation and maximum drawdown to decide if Sihuan Pharmaceutical is priced more or less accurately, providing market reflects its prevalent price of 0.17 per share. As Sihuan Pharmaceutical appears to be a penny stock we also recommend to double-check its information ratio numbers.
Sihuan Pharmaceutical's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Sihuan Pharmaceutical's valuation are provided below:Sihuan Pharmaceutical Holdings does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Sihuan |
Sihuan Pharmaceutical 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Sihuan Pharmaceutical's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Sihuan Pharmaceutical.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Sihuan Pharmaceutical on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Sihuan Pharmaceutical Holdings or generate 0.0% return on investment in Sihuan Pharmaceutical over 90 days. Sihuan Pharmaceutical is related to or competes with Curaleaf Holdings, Dermapharm Holding, Almirall, CanSino Biologics, HUTCHMED (China), Aspen Pharmacare, and Fagron NV. Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manuf... More
Sihuan Pharmaceutical Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Sihuan Pharmaceutical's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Sihuan Pharmaceutical Holdings upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.0973 | |||
| Maximum Drawdown | 133.81 |
Sihuan Pharmaceutical Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sihuan Pharmaceutical's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Sihuan Pharmaceutical's standard deviation. In reality, there are many statistical measures that can use Sihuan Pharmaceutical historical prices to predict the future Sihuan Pharmaceutical's volatility.| Risk Adjusted Performance | 0.0918 | |||
| Jensen Alpha | 1.49 | |||
| Total Risk Alpha | 0.3962 | |||
| Treynor Ratio | (9.85) |
Sihuan Pharmaceutical February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0918 | |||
| Market Risk Adjusted Performance | (9.84) | |||
| Mean Deviation | 4.19 | |||
| Coefficient Of Variation | 979.49 | |||
| Standard Deviation | 14.6 | |||
| Variance | 213.22 | |||
| Information Ratio | 0.0973 | |||
| Jensen Alpha | 1.49 | |||
| Total Risk Alpha | 0.3962 | |||
| Treynor Ratio | (9.85) | |||
| Maximum Drawdown | 133.81 | |||
| Skewness | 6.52 | |||
| Kurtosis | 48.81 |
Sihuan Pharmaceutical Backtested Returns
Sihuan Pharmaceutical is out of control given 3 months investment horizon. Sihuan Pharmaceutical owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.11, which indicates the firm had a 0.11 % return per unit of risk over the last 3 months. We have analyze and collected data for sixteen different technical indicators, which can help you to evaluate if expected returns of 1.61% are justified by taking the suggested risk. Use Sihuan Pharmaceutical Coefficient Of Variation of 979.49, variance of 213.22, and Risk Adjusted Performance of 0.0918 to evaluate company specific risk that cannot be diversified away. Sihuan Pharmaceutical holds a performance score of 8 on a scale of zero to a hundred. The entity has a beta of -0.15, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Sihuan Pharmaceutical are expected to decrease at a much lower rate. During the bear market, Sihuan Pharmaceutical is likely to outperform the market. Use Sihuan Pharmaceutical standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and day median price , to analyze future returns on Sihuan Pharmaceutical.
Auto-correlation | 0.03 |
Virtually no predictability
Sihuan Pharmaceutical Holdings has virtually no predictability. Overlapping area represents the amount of predictability between Sihuan Pharmaceutical time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Sihuan Pharmaceutical price movement. The serial correlation of 0.03 indicates that only 3.0% of current Sihuan Pharmaceutical price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.03 | |
| Spearman Rank Test | 0.03 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Sihuan Pharmaceutical Holdings reported net income of 416.51 M. This is 22.04% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 27.05% higher than that of the company.
Sihuan Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sihuan Pharmaceutical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sihuan Pharmaceutical could also be used in its relative valuation, which is a method of valuing Sihuan Pharmaceutical by comparing valuation metrics of similar companies.Sihuan Pharmaceutical is currently under evaluation in net income category among its peers.
Sihuan Fundamentals
| Return On Equity | -0.0487 | |||
| Return On Asset | -4.0E-4 | |||
| Profit Margin | (0.05) % | |||
| Operating Margin | (0) % | |||
| Current Valuation | 506.36 M | |||
| Shares Outstanding | 9.33 B | |||
| Shares Owned By Insiders | 55.02 % | |||
| Shares Owned By Institutions | 4.21 % | |||
| Price To Earning | 8.75 X | |||
| Price To Book | 0.81 X | |||
| Price To Sales | 0.41 X | |||
| Revenue | 3.29 B | |||
| Gross Profit | 2.45 B | |||
| EBITDA | 914.73 M | |||
| Net Income | 416.51 M | |||
| Cash And Equivalents | 5.25 B | |||
| Cash Per Share | 0.56 X | |||
| Total Debt | 844.75 M | |||
| Debt To Equity | 0.14 % | |||
| Current Ratio | 2.43 X | |||
| Book Value Per Share | 0.78 X | |||
| Cash Flow From Operations | 665.29 M | |||
| Earnings Per Share | 0.01 X | |||
| Number Of Employees | 3.9 K | |||
| Beta | 0.8 | |||
| Market Capitalization | 1.2 B | |||
| Total Asset | 14.5 B | |||
| Retained Earnings | 5.54 B | |||
| Working Capital | 4.66 B | |||
| Current Asset | 6.17 B | |||
| Current Liabilities | 1.51 B | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 14.5 B | |||
| Last Dividend Paid | 0.014 |
About Sihuan Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sihuan Pharmaceutical Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sihuan Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sihuan Pharmaceutical Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Sihuan Pink Sheet
Sihuan Pharmaceutical financial ratios help investors to determine whether Sihuan Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sihuan with respect to the benefits of owning Sihuan Pharmaceutical security.